April 1st always signals reflection and recalibration in the NHS with the issuing of new contracts and guidance. Typically this is tweaking that might make a slight difference to how conditions are prioritised or services are operated, something to be mindful of in your planning, but rarely anything to prompt major overhauls.

This time is different. Widespread structural change and significant job losses have fundamentally reshaped the health and care landscape. Responsibilities for commissioning, pathways and delivery are moving, and companies that treat this as business as usual risk finding their strategies misaligned with a system that no longer looks the way it did six months ago. All of this will have a material impact on individual brands.

These structural shifts are also beginning to reshape recruitment across the sector. As roles disappear, merge, or relocate, organisations are re-evaluating the profiles they need. Placing greater emphasis on adaptability, system awareness, and cross-functional capability. Candidates who understand the evolving NHS architecture are becoming significantly more valuable, while traditional role definitions are becoming less relevant.

In this article, Evolve and HACK explore the three biggest questions for pharma companies this year, and what it means for your engagement strategies.

Is our product actually going to have an impact at a population level?
It's easy to aggregate your patient numbers and consider this a population health impact, but the reality is far more nuanced.

Population health means two things: impact and scale. To be considered a population-level intervention, a therapy must do more than treat symptoms. The wider benefits need to be quantified and evidenced: reductions in comorbidities, mental health improvements, return to work. These are some of the outcomes that amplify clinical benefits and drive system-level buy-in. On scale, numbers matter too. Systems are looking to maximise the value from every pound spent, so a drug with a strong headline ROI makes the investment case far easier to land.

If your evidence doesn't drive messaging that clearly articulates both impact and scale, you'll struggle to win buy-in that you have a population-level product.

From a recruitment perspective, this is driving demand for talent with strong health economics, outcomes research, and real-world evidence expertise. Organisations are increasingly seeking individuals who can translate complex data into compelling system-level narratives, meaning competition for these skillsets is intensifying across pharma and consultancy roles.

How does our product really impact on pathways and services?
With limited capacity to absorb change, understanding what you're actually asking systems to do in order to adopt your product requires thorough preparation.

The shift of care from hospital to community is happening. Many medicines can support this but the pathways you thought you were integrating into may be changing, and with them, the impact you assumed you'd have on services. A new test or a different mode of administration may seem like minor adjustments, but in a system that's actively reorganising itself, even small pathway changes can create significant friction.

No part of the health and care system has spare capacity, so any ask to review pathways to accommodate your product needs to be clear and well-evidenced. You need a precise understanding of how those pathways are evolving to be able to present your product as a solution, not a complication.

This evolving complexity is also influencing hiring priorities. There is growing need for individuals with deep pathway knowledge, service redesign experience, and the ability to engage credibly with both primary and community care stakeholders. Hybrid roles blending medical, commercial, and system engagement capabilities are becoming more common, reflecting the need for more integrated approaches.

Are we certain our customer is the same as it was on March 31st?
Here's the uncomfortable truth: many of your customers may not yet fully understand their own new responsibilities. Information is still being drip-fed across the system, and many teams are still settling into new ways of working. That creates a short window to get ahead and a real opportunity for those who do.

Shifting responsibilities have made material differences to who will be able and motivated to invest in your product. Decision-making is now more likely to sit with providers than ICBs, whose role is now more strategic. For primary care and population health medicines, you may need to re-invest in broader engagement, having previously seen ICBs as the primary route to uptake. For specialised medicines, the introduction of OPICs (Offices of Pan-ICB Commissioning) may create new leverage points across therapy areas, while ICBs retain budgets for services delegated from NHS England.

Validating your customer base now isn't housekeeping, it's a prerequisite for in-year impact. Getting ahead of the confusion and guiding customers through the changes will be a genuine differentiator in gaining traction in 2026.
These shifts are also redefining customer-facing roles. Recruitment is increasingly focused on candidates who can navigate ambiguity, build relationships across newly formed structures, and operate effectively without clearly defined stakeholder maps. Agility, stakeholder mapping, and influencing skills are becoming core hiring criteria, particularly for field-based and account management roles.

These aren't just strategic questions, they have direct implications for the capabilities and people you need to execute against them.

Taken together, these trends point to a broader recalibration of talent strategies across the sector. Companies that align their recruitment approach with the realities of the evolving NHS, prioritising adaptable, system-literate, and insight-driven individuals, will be better positioned to execute effectively, while those that do not risk capability gaps at a critical moment.

We invite you to get in touch when you come to review your brand strategies and customer segmentation, to optimise the impact of all your engagements.

Nonfed:
HACK is convening an online conference on July 10th, exploring the reality of implementing change in the evolving NHS. This event provides a unique platform to upskill on what matters to the NHS right now, hearing directly from those who will be shaping the new systems and providers.
Bringing together system leaders and experts, Nonfed will shine a light on what is needed from industry to influence system and pathways through 2026.

The conference platform encourages networking, with virtual exhibitor booths available to showcase examples of solutions or best practice.

See more and register at nonfed.live. Evolve clients can secure a 50% discount on tickets using the promo code EVOLVE2026